abacavir
Antiinfectives for systemic use (J05)US regulatory status: approved.
biotech Β· Essential Tremor Β· Systemic Lupus Erythematosus
Chongqing Precision Biotech
Chongqing Precision Biotech Co., Ltd
Chongqing Precision Biotech drug portfolio β 57 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
ιεΊεΈεδΈε€§ιι«η§εδΈεAζ , Chongqing, CN HQ
2016 Founded
5 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- ιεΊεΈεδΈε€§ιι«η§εδΈεAζ , Chongqing, CN
- Founded
- 2016
- Employees
- 5
- Programs
- 109
- Drugs
- 57
- Patents
- 158
Chongqing Precision Biotech pipeline
Portfolio lens on 57 drugs and development assets β regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Chongqing Precision Biotech drug portfolio β 57 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
-
Development asset linked to Chongqing Precision Biotech in public FDA and regional records.
-
adalimumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
afatinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Mechanism: Epidermal growth factor receptor erbB1 inhibitor.
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to Chongqing Precision Biotech in public FDA and regional records.
-
asenapine
Nervous system (N05)US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
Development asset linked to Chongqing Precision Biotech in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
canakinumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-1 beta.
- Target
- Interleukin-1 beta
- Mechanism
- Interleukin-1 beta inhibitor
-
Development asset linked to Chongqing Precision Biotech in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Chongqing Precision Biotech in public FDA and regional records.
-
Development asset linked to Chongqing Precision Biotech in public FDA and regional records.
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M3.
- Target
- Muscarinic acetylcholine receptor M3
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Cystine.
- Target
- Cystine
- Mechanism
- Cystine reducing agent
-
Development asset linked to Chongqing Precision Biotech in public FDA and regional records.
-
erlotinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Chongqing Precision Biotech's portfolio. Mechanism: Epidermal growth factor receptor erbB1 inhibitor.
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
florbetaben (18f)
Various (V09)Various (V09) compound in Chongqing Precision Biotech's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
fluciclovine (18f)
Various (V09)Various (V09) compound in Chongqing Precision Biotech's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to Chongqing Precision Biotech in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA polymerase (alpha/delta/epsilon).
- Target
- DNA polymerase (alpha/delta/epsilon)
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
gefitinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to Chongqing Precision Biotech in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Chongqing Precision Biotech in public FDA and regional records.
-
Development asset linked to Chongqing Precision Biotech in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
Development asset linked to Chongqing Precision Biotech in public FDA and regional records.
-
Development asset linked to Chongqing Precision Biotech in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor agonist
-
melphalan
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
melphalan flufenamide
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Chongqing Precision Biotech's portfolio.
-
osimertinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Chongqing Precision Biotech's portfolio. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to Chongqing Precision Biotech in public FDA and regional records.
-
Development asset linked to Chongqing Precision Biotech in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha.
- Target
- Adrenergic receptor alpha
- Mechanism
- Adrenergic receptor alpha antagonist
-
Development asset linked to Chongqing Precision Biotech in public FDA and regional records.
-
Development asset linked to Chongqing Precision Biotech in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Chongqing Precision Biotech in public FDA and regional records.
-
Development asset linked to Chongqing Precision Biotech in public FDA and regional records.
-
Development asset linked to Chongqing Precision Biotech in public FDA and regional records.
-
Development asset linked to Chongqing Precision Biotech in public FDA and regional records.
-
Development asset linked to Chongqing Precision Biotech in public FDA and regional records.
-
Development asset linked to Chongqing Precision Biotech in public FDA and regional records.
-
Development asset linked to Chongqing Precision Biotech in public FDA and regional records.
-
Development asset linked to Chongqing Precision Biotech in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Vasopressin receptor.
- Target
- Vasopressin receptor
- Mechanism
- Vasopressin receptor agonist